SCHEMBL2238809

SCHEMBL2238809

N#Cc1cncc(-c2cc(NCc3cccc4[nH]ccc34)nc(-c3ccccn3)n2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 10/20 0.41
CLK4 Q9HAZ1 10/20 0.41
CYP3A4 P08684 10/20 0.41
CYP2C19 P33261 9/20 0.41
ALDH1A1 P00352 8/20 0.41
MAPK1 P28482 6/20 0.41
CYP2D6 P10635 5/20 0.41
USP2 O75604 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 5/20 0.40
LMNA P02545 3/20 0.37
HSD17B10 Q99714 3/20 0.37
ALOX15 P16050 1/20 0.37
GRM5 P41594 2/20 0.37
ABCG2 Q9UNQ0 2/20 0.36
ABCB1 P08183 1/20 0.36
SLC2A1 P11166 1/20 0.36
CYP2C9 P11712 3/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240050 0.86 CYP3A4 (0.46) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL2239320 0.83 KMT2A (0.47) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL2238560 0.83 TGFBR1 (0.35) CYP1A2CLK4CYP3A4CYP2C19CYP2D6
SCHEMBL2237770 0.82 CYP1A2 (0.47) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL2241460 0.77 CDK4 (0.47) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL3721234 0.75 CYP3A4 (0.41) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL3718165 0.75 GPR39 (0.38) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL3721684 0.75 GPR39 (0.38) CYP1A2CLK4CYP3A4CYP2C19CYP2D6
SCHEMBL2240341 0.75 CDK4 (0.50) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1
SCHEMBL2238648 0.74 CYP2A6 (0.46) CYP1A2CLK4CYP3A4CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP claimed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US claimed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US claimed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP claimed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO claimed
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors ALK, ACVR1, MUSK CYP1A2 929/4885CLK4 4726/4885CYP3A4 1519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.